60 Degrees Pharmaceuticals Announces FDA Orphan Drug Designation For Tafenoquine To Treat Acute Babesiosis

Author: Benzinga Newsdesk | June 11, 2024 08:00am

• With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for certain incentives, including market exclusivity, tax credits, and exemption from certain FDA filing fees.
• 60 Degrees Pharmaceuticals recently announced it has entered into an agreement with Tufts Medical Center in Boston to conduct the world's first clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients.
• FDA orphan drug designation is granted for therapeutic candidates that may prevent or treat a rare disease or condition, such as acute babesiosis.

Posted In: SXTP